Small Molecules
11 Results were found on Technologies
Sub Category Name
Inhibition of the Pax8 Transcription Factor as a Novel Therapeutic Approach for Ovarian and Endometrial Cancer
OUTLINEThe PAX8 transcription factor is essential for ovarian cancer proliferation, and its silencing in ovarian and endometrial cancer cells leads to apoptosis 1,2. PAX8 expression in other tissues is restricted to non-essential organs, suggesting that it is a good target for therapy with minimal side effects 3,4. We propose a novel anti-ovarian and -endometrial cancer […] Read More >
SK4 K+ channel blockers: a new treatment for cardiac atrial fibrillation
We discovered a previously unidentified target in the heart, namely the SK4 calcium-activated K+ channels, which are functionally expressed in pacemaker cells as well as in atrial and ventricular cardiomyocytes. They are crucial for proper cardiac function and represent a completely new therapeutic target for the treatment of cardiac arrhythmias. SK4 channel blockers successfully prevented […] Read More >
Macrolid Induced Correction of Premature Stop Codons: A novel Treatment for Colorectal Cancer
Restoration of premature termination codons (PTCs) caused by nonsense mutations for the treatment of Familial Adenomatous Polyposis. The Need Familial Adenomatous Polyposis (FAP) is a high penetrance devastating syndrome manifested by dozens to thousands of colonic adenomas. FAP patients require tight supervision and eventually undergo surgery, to prevent inevitable development of colorectal cancer (CRC) by […] Read More >
Repurposing of Antibiotics for treating APC (Adenomatous Polyposis Coli) Related Colorectal Cancer
Restoration of Adenomatous Polyposis Coli (APC) gene expression by means of antibiotic erythromycin for the treatment of Familial Adenomatous Polyposis. The Technology:Treatment for APC by conventional antibiotics to regulate adenoma growth and delay the need for preventive surgery in Familial Adenomatous Polyposis (FAP) patients. The Need: FAP is a high penetrance devastating syndrome manifested by dozens […] Read More >
Novel Bcr-Abl1 Inhibitors for Treating Imatinib Resistance Cancer
The BCR-ABL1 fusion gene is the hallmark of the Philadelphia chromosome-positive (Ph+) leukemia, creating a constitutively active ABL1 tyrosine kinase. Current therapy relies on the FDA-approved tyrosine kinase inhibitors (TKIs) such as imatinib (Gleevec®), which target the ATP binding site of the BCR-ABL1 kinase. Unfortunately, the acquisition of point mutations in the ATP binding site […] Read More >
Protection of Oxygen-Sensitive-Enzymes by Peptide Hydrogel
Molecular oxygen (O2) is a highly reactive oxidizing agent harmful to many biological and industrial systems. A simple encapsulation in a protective aqueous environment of O2 -sensitive reactions is of need. Self-assembling peptide-based hydrogels are simple hydrogels that can be combined with a wide variety of reagents and are able to encage O2 and significantly limit its […] Read More >
Homocysteine fibrillar assemblies display crosstalk with Alzheimer’s disease amyloid polypeptide
High levels of homocysteine (Hcy) are reported as a risk factor for Alzheimer’s disease (AD). Correspondingly, inborn hyperhomocysteinemia is associated with an increased predisposition to the development of dementia in later stages of life. Furthermore, despite the apparent association between protein aggregation and AD, attempts to develop a therapy that targets explicitly this process have […] Read More >
Development of Alzheimer Disease therapy based on counteracting the pathological effects of ApoE4
Alzheimer’s disease (AD) is the most common cause of dementia and is the outcome of progressive brain cells death. Due to the disorder’s heterogeneity and in view of the variety of pathological mechanisms inducing the disease we have undertaken an innovative – science based (Animal model) approach, which is presented here. Our unique approach […] Read More >
Therapeutic Targeting of PD-1/PD-L1 blockade by Novel Small-molecule Inhibitors
Interactions between programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) lead to the evasion of cancer cells from an efficient immune response. The inhibition of PD-L1/PD-1 has prevented or reversed exhausted T cells, thus enhancing antitumor T-cell responses. In fact, immune checkpoint blockade targeting the PD-1 axis has become one […] Read More >
Therapeutic Targeting of CD45 by Novel Agents to Immunotherapy Non-Responders Tumors
Therapeutic advances in cancer immunotherapy have rapidly emerged in the past few years, reflecting the importance of the interaction between the human immune system and cancer. Despite the successful application of immunotherapy across a broad range of human cancers, only a minority of patients with terminal cancer experience life-altering durable survival from these therapies. These […] Read More >
